Plain-English translation of NCT05827159 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new way to help people with moderate to severe alcohol use disorder by starting treatment right in the emergency department. Researchers are comparing two approaches: one that offers brief counseling and referral to treatment, and another that adds medications โ naltrexone and gabapentin โ started immediately in the ED. The goal is to see if giving people the medication right away, rather than waiting, helps more people stick with treatment and reduce their drinking.
Many people with alcohol use disorder go to emergency departments but never end up getting treatment afterward. This trial exists to find out whether starting this medication right away in the ED โ at a moment when someone is already seeking care โ can close the gap between people who need help and people who actually receive it.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you qualify, you'll be randomly assigned to receive either counseling alone or counseling plus medications started right in the ED. If you receive the medication approach, you'll get your first doses of naltrexone (as an injection or a pill) and gabapentin in the emergency department, along with take-home doses to continue treatment. You'll have follow-up visits and calls to track how you're doing and support your recovery over the study period.
AI-generated summary from trial data ยท Oct 12, 2026 ยท Not medical advice
United States